Instead of expanding at its New Jersey headquarters, Legend Biotech opened its new R&D center in Philadelphia. This strategic move aims to attract specialized scientific talent by deliberately locating in a key innovation hub for cell therapy, demonstrating a "go to the talent" growth strategy.

A new biotech model attracting global VCs is emerging in Japan. It pairs the country's high-quality, surprisingly low-cost R&D talent with US management and venture funding. The Japanese government is accelerating this trend with powerful incentives, like a non-dilutive "two-for-one" matching grant program for accredited investors.

Despite potential language or tax hurdles, Japan's high quality of life—including safety, public transport, and cuisine—is a powerful magnet for top international talent. Startups find it's a significant competitive advantage, making it easier to recruit globally than many expect.

To bridge its translational research gap, Japan’s Agency of Medical Research and Development offers a unique fund. For qualified startups, it matches every dollar of venture capital investment with two dollars of non-dilutive government funding, providing crucial capital to advance early-stage assets without giving up equity.

Moving first-in-human studies to countries like Australia and China is now a core business strategy, not just a cost-saving measure. It allows U.S. biotechs to navigate a more flexible regulatory environment and accelerate development timelines.

Unlike in the US, early-stage Japanese startups, including high-risk biotech ventures, can secure low-interest, long-term loans from regional banks. This provides a powerful source of non-dilutive capital, allowing founders to extend runway while preserving equity.

Complement Therapeutics intentionally built a presence across the UK, Germany, and the US to optimize talent acquisition. This cross-geographical structure allows them to hire the best experts in a specialized field like gene therapy, irrespective of their location, without being constrained by a single talent pool or dealing with complex relocations.

Instead of traditional regional HQs, firms should adopt a "capability-first" model. This involves strategically placing functions where excellence exists: basic science in Japan, clinical scale in China, and biologics in Korea. This creates a more efficient, interconnected global R&D engine, breaking from geography-based silos.

Japan's biotech ecosystem is evolving with a new, successful model for creating cross-border companies. US venture firms are partnering with Japanese academia, combining American management expertise and capital with Japan's strong science and cost-effective R&D to build globally competitive biotechs from their inception.